Safety study of VYLOY for stomach or GEJ cancer in South Korea
Treatments studied
Part of Cancer clinical trials.
This study monitors the safety of VYLOY (a cancer medicine) given to people in South Korea with stomach or gastroesophageal junction cancer. It helps doctors learn more about real-world side effects and how well patients do on treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction cancer.
- Your doctor has decided to treat you with VYLOY injection as normally prescribed in South Korea.
- You are not in another clinical trial where you are given an experimental drug.
- You do not have any medical condition that would make VYLOY unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
This study looks at how well zolbetuximab works when combined with chemotherapy in people with advanced stomach or gastroesophageal junction cancer. It aims to help doctors understand the best ways to use this treatment in everyday practice.
This early access program offers the investigational drug zolbetuximab for people with advanced stomach cancer that has a specific protein marker. The study aims to make this targeted treatment available before it is fully approved, potentially helping those who have limited options.
This study tests a new drug called zolbetuximab added to standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer. It may help slow the cancer's growth.
This study is collecting real-world safety information about Lorviqua (lorlatinib) in adults in Korea who have ALK-positive metastatic non-small cell lung cancer. It helps monitor side effects and safe use after the medicine is already on the market.
This trial tests a combination of adebrelimab (an immunotherapy) with either two other experimental drugs (SHR-A1811 or SHR-A1904) plus chemotherapy, or another drug (SHR-8068), as a first treatment for gastric or gastroesophageal junction adenocarcinoma. It aims to find if these combos work better than standard care.
Hear when a new Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.